OncoMatch/Clinical Trials/NCT04214990
Aspirin Use for Gastric Cancer Prevention in the Early Gastric Cancer Patients
Is NCT04214990 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Aspirin 100mg for aspirin.
Treatment: Aspirin 100mg — This study aimed to investigate the effect of low-dose (100 mg) asprin on the prevention of gastric cancer in the early gastric cancer patients with negative H. pylori status who underwent endoscopic submucosal dissection.
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastric Cancer
Disease stage
Required: Stage CATEGORY 4, CATEGORY 5 (Vienna classification of gastrointestinal epithelial neoplasia)
Grade: high-grade (Vienna classification)
category 4 [non-invasive high grade neoplasm] or category 5 [invasive neoplasia] according to the Vienna classification
Prior therapy
Must have received: endoscopic resection
who underwent endoscopic resection for high-grade adenoma or early gastric cancer
Cannot have received: gastrectomy
Previous gastrectomy history
Cannot have received: aspirin (secondary prevention of cardiovascular/cerebrovascular disease)
Patients who received aspirin for the secondary prevention of cardiovascular diseases or cerebrovascular diseases
Cannot have received: regular aspirin use
Regular aspirin uses (more than 3 times a week) with 2 months before screening visit
Cannot have received: anticoagulant or antiplatelet drugs
Patients who used anticoagulants or antiplatelet drugs for therapeutic purpose
Cannot have received: non-curative resection
Non-curative resection of early gastric cancer after endoscopic resection
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify